NHS England approves four-in-one Stribild (Quad) for limited use
1 October 2013. Related: Antiretrovirals.
Antiretrovirals
Dolutegravir approved in the US
1 October 2013. Related: Antiretrovirals.
ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK
1 October 2013. Related: Antiretrovirals.
From sky high to CHAI* – what needs to be done about dolutegravir pricing?
1 October 2013. Related: Antiretrovirals, Treatment access.
Pharmacokinetics of etravirine with once-daily and twice-daily dosing
1 October 2013. Related: Antiretrovirals, PK and drug interactions.
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
25 July 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
25 July 2013. Related: Conference reports, Antiretrovirals.
Non-standard combinations: NRTI-sparing combinations
25 July 2013. Related: Conference reports, Antiretrovirals.
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Decreased growth in ART exposed uninfected infants in Botswana
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Antiretrovirals, doses and formulations for children
25 July 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
25 July 2013. Related: Antiretrovirals, Treatment access.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
The antiretroviral pipeline 2013
30 June 2013. Related: Pipeline report, Antiretrovirals.
The paediatric antiretroviral pipeline
30 June 2013. Related: Pipeline report, Antiretrovirals, Paediatric care.
Small increase in birth defects in the French Perinatal Cohort
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Uptake and retention in Malawi’s Option B+ programme
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
EU approves four-in-one Stribild
29 May 2013. Related: Antiretrovirals.
FDA delays decision for elvitegravir and cobicistat
29 May 2013. Related: Antiretrovirals.
EU approval for raltegravir in children aged 2 years and older
29 May 2013. Related: Antiretrovirals, Paediatric care.
FDA update label for paediatric efavirenz and capsule sprinkle formulation
29 May 2013. Related: Antiretrovirals, Paediatric care.
Cobicistat compared to ritonavir to boost atazanavir in treatment naive patients
29 May 2013. Related: Antiretrovirals.
ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc
1 April 2013. Related: Conference reports, Antiretrovirals.
ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations
1 April 2013. Related: Conference reports, Antiretrovirals.
Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Pharmacokinetics of currently available antiretroviral options for young children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Safety of transplacental raltegravir in neonates and washout pharmacokinetics
1 April 2013. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Tenofovir use in children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
ddI resistance in South African children failing an abacavir or d4T based first-line regimen
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, Drug resistance.
Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)
1 April 2013. Related: Antiretrovirals, PK and drug interactions.
EU adopts positive opinion for decision on regulatory approval of Quad
1 April 2013. Related: Antiretrovirals.
Gilead Sciences announces fourth quarter and full year 2012 financial results
1 April 2013. Related: Antiretrovirals.
ViiV stops development of NNRTI lersivirine
1 April 2013. Related: Antiretrovirals.
Nelfinavir non-renewal of marketing authorisation in the EU
1 April 2013. Related: Antiretrovirals.
START study increases sample size: additional 600 participants to be older than 35
1 April 2013. Related: Antiretrovirals, Treatment strategies.
WHO statement: generic antiretroviral therapy is safe and effective
1 February 2013. Related: Treatment alerts, Antiretrovirals.
Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health.
Differences by age for women in response to initial ART: meta-analysis from clinical studies submitted to the FDA
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health.
Lopinavir/ritonavir in pregnancy: results from a systematic review
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Dolutegravir submitted to EU, US and Canadian regulatory agencies
1 February 2013. Related: Antiretrovirals.
Darunavir: new oral suspension and 800 mg formulations approved in EU
1 February 2013. Related: Antiretrovirals.
US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance
1 February 2013. Related: Antiretrovirals, Drug resistance.
Dolutegravir: integrase resistance and the impact of the background regimen
1 December 2012. Related: Conference reports, Antiretrovirals.
Updated results on Quad: 96 week data from phase 3 studies
1 December 2012. Related: Conference reports, Antiretrovirals.
Darunavir 800 mg tablet approved in the US
1 December 2012. Related: Antiretrovirals.
Study summaries from ICAAC 2012
1 October 2012. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Antiviral activity in vitro with S/GSK1265744
1 October 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz interaction studies with TB compounds bedaquiline and delamanid
1 October 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
HPTN-052: clinical advantages from earlier treatment
1 October 2012. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Online video interviews between researchers and activists
1 October 2012. Related: Conference reports, Antiretrovirals, Treatment access, HIV prevention and transmission, Cure-related research, Other news.
FDA approves Quad in US: price may prohibit UK access
1 October 2012. Related: Antiretrovirals.
Merck acquires CMX157 and EFdA and starts phase 2 study for new NNRTI
1 October 2012. Related: Antiretrovirals.
Roche to discontinue production of nelfinavir and saquinavir 200 mg hard capsules
1 October 2012. Related: Antiretrovirals.
New booster – cobicistat as an alternative to ritonavir
1 August 2012. Related: Conference reports, Antiretrovirals.
Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study
1 August 2012. Related: Conference reports, Antiretrovirals.
Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients
1 August 2012. Related: Conference reports, Antiretrovirals.
In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials
1 August 2012. Related: Conference reports, Antiretrovirals.
Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks
1 August 2012. Related: Conference reports, Antiretrovirals.